Non-Dilutive Funding Fuels MiNK Therapeutics' Phase 2 Program Advancements, 2H 2026 Readouts Expected
summarizeSummary
MiNK Therapeutics reported its Q4 and Full Year 2025 results, emphasizing significant operational advancements and non-dilutive funding across its clinical pipeline. The company is progressing its agenT-797 therapy in a randomized Phase 2 trial for hypoxemic pneumonia/ARDS, with clinical readouts anticipated in 2H 2026. Furthermore, the externally funded GVHD program is advancing, with first dosing expected in May 2026 and preliminary clinical data in 2H 2026. This news builds on the recent 8-K from March 27th, which discussed strategic initiatives, now clarified by the securing of up to $1.1 million in non-dilutive funding and a double-digit revenue share through the C-Further Consortium collaboration. These developments provide crucial capital and clear clinical catalysts for the company, which is particularly impactful for a clinical-stage biopharmaceutical firm.
At the time of this announcement, INKT was trading at $10.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $49.4M. The 52-week trading range was $6.34 to $76.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.